Azido Impurities in Sartan APIs: ICH M7 Control Strategies and Analytical Testing Options
Azido impurities in sartan active pharmaceutical ingredients are governed by ICH M7, which sets a TTC of 1.5 µg person⁻¹ day⁻¹. Control strategies combine risk assessment, supplier qualification and validated analytical methods such as LC‑MS/MS or GC‑MS, with limits typically below 0.1 ppm.
What are the ICH M7 guidelines for azido impurities in sartan APIs?
ICH M7 provides a framework for assessing and controlling mutagenic impurities. Azide (CAS 2212‑52‑0) is classified as a Class 2 mutagenic impurity, meaning its acceptable intake is limited by the Threshold of Toxicological Concern (TTC) of 1.5 µg person⁻¹ day⁻¹. For a typical daily dose of a sartan (e.g., 80 mg of losartan), this translates to an impurity limit of roughly 0.19 ppm (µg g⁻¹) in the API. The guideline requires a documented risk assessment, justification of the TTC‑derived limit, and a control strategy that ensures the impurity does not exceed the limit throughout the product lifecycle.
How can manufacturers implement control strategies for azido impurities under ICH M7?
Control strategies are built around three pillars:
- Risk assessment and design of experiments – Early‑stage synthesis routes are examined for azide‑forming steps (e.g., nucleophilic substitution with NaN₃). Computational tools (e.g., OECD QSAR Toolbox) can predict mutagenic potential, guiding route optimisation.
- Supplier qualification and material control – Suppliers must provide a Certificate of Analysis (CoA) confirming azide levels below the TTC‑derived limit. Audits should verify compliance with ISO 9001 and REACH registration, and the supplier’s own impurity control plan.
- In‑process monitoring and final‑product testing – Critical process parameters (temperature, reaction time, work‑up pH) are monitored to prevent azide formation. Final API batches are tested using a validated analytical method (see next section). Any batch exceeding the limit triggers a root‑cause investigation and, if necessary, a product recall.
Molekula offers reference standards and analytical services that can be incorporated into a supplier‑qualification programme, but the responsibility for compliance remains with the API manufacturer.
Which analytical techniques are suitable for detecting azido impurities in sartan APIs?
The low acceptable limit (≤0.2 ppm) demands highly sensitive and selective methods. The most common techniques are:
| Technique | Typical LOD/LOQ* | Advantages | Limitations | |-----------|------------------|------------|-------------| | LC‑MS/MS (MRM mode) | 0.05–0.1 ppm | High sensitivity, matrix tolerance, quantification with isotope‑labelled internal standard. | Requires expensive instrumentation and method development. | | GC‑MS (selected ion monitoring) | 0.02–0.05 ppm | Excellent for volatile or derivatised azides, robust separation. | Azides may decompose; derivatisation step adds complexity. | | HPLC‑UV (254 nm) after derivatisation with 2‑mercaptoethanol | 0.2 ppm | Simple equipment, suitable for routine release testing. | Lower sensitivity, potential interferences from co‑eluting UV‑active impurities. | | Capillary electrophoresis with laser‑induced fluorescence | 0.01 ppm | Very low LOD, small sample volume. | Limited to specialised labs, method transfer can be challenging. |
*LOD = limit of detection; LOQ = limit of quantification. The choice of method depends on the laboratory’s capability, the API matrix, and the required throughput. Validation parameters must meet ICH Q2(R1) criteria: specificity, linearity (typically 0.1–10 ppm), accuracy (recovery 80–120 %), precision (RSD ≤ 5 %).
What are the acceptance limits for azido impurities in sartan APIs according to ICH M7?
The TTC‑derived limit of 0.19 ppm for an 80 mg daily dose is the default. However, the actual acceptance limit may be adjusted based on:
- Dose size – Higher daily doses lower the permissible impurity concentration proportionally.
- Manufacturing route – If the synthetic route eliminates azide‑forming steps, a justification may allow a higher limit, provided a thorough risk assessment is documented.
- Analytical capability – If the validated method reliably quantifies down to 0.05 ppm, the limit can be set at the TTC value with a safety margin (e.g., 0.1 ppm) to accommodate analytical uncertainty.
Regulatory submissions must include a justification table showing the calculated TTC limit, the chosen acceptance limit, and the analytical method’s performance characteristics.
How should data be reported and documented for azido impurity testing?
ICH Q7 and M7 require a complete data package:
- Analytical method description – Include column type, mobile phase composition, gradient, MS parameters, and validation summary.
- Batch analysis results – Tabulate each batch’s measured azide concentration, LOD/LOQ, and compliance statement.
- Stability data – Demonstrate that azide levels remain below the limit throughout the product’s shelf‑life under ICH‑qualified storage conditions.
- Change control records – Any alteration to the synthetic route, analytical method or supplier must be recorded and re‑assessed against the TTC.
Electronic Laboratory Notebooks (ELNs) and a centralised Quality Management System (QMS) facilitate traceability. When submitting to agencies (EMA, FDA), the impurity data are presented in the IMPD (Investigational Medicinal Product Dossier) or the CMC section of the NDA, with cross‑references to the risk assessment report.
Frequently asked questions
Q1: Can azido impurities be removed by simple washing? A: Azides are often tightly bound or present as residual reagents; washing alone is insufficient. Process steps such as aqueous work‑up at pH 7–8, followed by activated carbon treatment, are more effective.
Q2: Is a 0.1 ppm limit acceptable for all sartan APIs? A: It is acceptable when the daily dose is ≤ 100 mg and the analytical method demonstrates an LOQ ≤ 0.05 ppm. Larger doses require proportionally lower limits.
Q3: What is the preferred internal standard for LC‑MS/MS azide analysis? A: An isotopically labelled azide analogue (e.g., ^15N‑azide) provides the best compensation for matrix effects and instrument drift.
Q4: How often should the analytical method be re‑validated? A: At least once every two years, or whenever there is a change in instrumentation, column lot, or significant shift in performance metrics.
Frequently asked
Can azido impurities be removed by simple washing?
Azides are often tightly bound or present as residual reagents; washing alone is insufficient. Process steps such as aqueous work‑up at pH 7–8, followed by activated carbon treatment, are more effective.
Is a 0.1 ppm limit acceptable for all sartan APIs?
It is acceptable when the daily dose is ≤ 100 mg and the analytical method demonstrates an LOQ ≤ 0.05 ppm. Larger doses require proportionally lower limits.
What is the preferred internal standard for LC‑MS/MS azide analysis?
An isotopically labelled azide analogue (e.g., ^15N‑azide) provides the best compensation for matrix effects and instrument drift.
How often should the analytical method be re‑validated?
At least once every two years, or whenever there is a change in instrumentation, column lot, or significant shift in performance metrics.
Related reading
-
Regulatory
Harmonising USP, Ph. Eur. and JP Grades: Essential Checks for Multi‑Market Excipient Buyers
Excipient grades defined by USP, Ph. Eur. and JP differ in monograph limits, impurity specifications and testing methods. Buyers must compare assay ranges, impurity thresholds, analytical techniques, and regulatory documentation to ensure that a single material can satisfy all three pharmacopeias without compromising quality or compliance.
Nov 18, 2026 · 6 min read -
Regulatory
Regulatory considerations for using AI‑generated synthetic routes in IND submissions
AI‑generated synthetic routes can be included in IND dossiers, but they must satisfy FDA and ICH requirements for documentation, reproducibility, risk assessment and data integrity. Key steps include validating the AI model, providing detailed synthetic procedures, and demonstrating compliance with GMP, GxP and relevant chemical safety regulations.
Nov 16, 2026 · 5 min read -
Regulatory
Guidelines for Safe Handling and Transport of Bulk Peracid Oxidisers under Revised ADR Rules
Bulk peracid oxidisers are now classified as Class 8 corrosive substances under the revised ADR, with stricter limits on concentration, temperature and packaging. Compliance requires UN‑specified containers, temperature‑controlled transport, mandatory PPE, detailed documentation and emergency response plans. Molekula supplies compliant bulk grades and safety data.
Nov 14, 2026 · 6 min read -
Regulatory
Impact of US Inflation Reduction Act Tax Credits on Domestic Production of Specialty Amino Acids
The US Inflation Reduction Act (IRA) provides tax credits for domestic manufacturing of specialised amino acids, reducing effective tax rates by up to 30 %. This incentivises reshoring, lowers supply‑chain risk and can modestly lower product costs, though the effect varies by grade and scale.
Nov 13, 2026 · 5 min read